Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hikma Pharmaceuticals ( (GB:HIK) ) has issued an update.
Hikma Pharmaceuticals has continued executing its previously announced $250 million share buyback, repurchasing 239,194 ordinary shares between 13 and 17 April 2026 on the London Stock Exchange through Citigroup Global Markets. The company intends to cancel these shares, having now acquired a total of 4,374,095 shares at a cost of £54.8 million, leaving 217,512,358 voting shares in issue and signalling an ongoing effort to optimise its capital structure and enhance shareholder returns.
The latest tranche of repurchases increases the number of shares held in treasury to 12,833,233, while maintaining the total voting rights at 217,512,358. By reducing its free float and committing substantial funds to the programme, Hikma is reinforcing confidence in its valuation and capital position, with implications for earnings per share metrics and the ownership profile of remaining shareholders.
The most recent analyst rating on (GB:HIK) stock is a Buy with a £1800.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.
Spark’s Take on HIK Stock
According to Spark, TipRanks’ AI Analyst, HIK is a Neutral.
The score is held back primarily by weakening cash generation and a notably bearish technical trend (oversold and trading below key moving averages). These are partially offset by attractive valuation (low P/E and strong dividend yield) and a constructive earnings-call outlook supported by guidance comfort and a GBP 250m buyback, despite near-term injectable headwinds.
To see Spark’s full report on HIK stock, click here.
More about Hikma Pharmaceuticals
Hikma Pharmaceuticals, listed in London and on Nasdaq Dubai, is a multinational generic and specialty pharmaceutical company. It focuses on developing, manufacturing and marketing injectable, branded and non‑branded generic medicines, serving hospitals and healthcare systems across global markets.
Average Trading Volume: 1,408,086
Technical Sentiment Signal: Sell
Current Market Cap: £2.91B
For detailed information about HIK stock, go to TipRanks’ Stock Analysis page.